Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

GREY:ATBPF - Post Discussion

Antibe Therapeutics Inc(Pre-Merger) > Webinar w $ATE CEO Dan Legault - Mon Nov 21 @ 4:15PM ET
View:
Post by bmreed on Nov 21, 2022 11:36am

Webinar w $ATE CEO Dan Legault - Mon Nov 21 @ 4:15PM ET

Webinar - Antibe Therapeutics $ATE w/ CEO Dan Legault

Mon, November 21 at 4:15pm ET / 1:15pm PT

Q&A with Radius Research 

Register Here - https://us02web.zoom.us/webinar/register/5216686324941/WN_NEICOjy7TOCAAlEzN3441w

 

CEO Dan Legault will be providing a corporate update, including the progress of its lead drug otenaproxesul, targeting acute pain, as well as updates on ATB-352 and its inflammatory bowel disease (IBD) program.

Comment by Doccole on Nov 21, 2022 5:45pm
He is difficult to listen to. ok, we will continue to be stuck here a long time.  Heard lots of the same stuff.   Did he say 1 billion for USA sales? 
Comment by guilelesscat on Nov 21, 2022 6:48pm
I mean it gave a lot more color. Now we know the bottleneck is with logistics, which should be cleared up in March.  Yes, 1 billion for USA sales that is correct.  All in all, it was a informative call, and worth the listen. Who knows, maybe he's right and soon we'll be looking at a 9x or 10x jump.  otherwise... It fails the placebo trials, and the stock craders. All we ...more  
Comment by MrMugsy on Nov 21, 2022 7:20pm
I'd assume that's $1B USD for post-op in the USA alone - then you have Europe, Japan and LATAM to deal. Then we have other acute. Then working on an IV form for the futrure. Then you still have additional future chronic sales. Lots of milestone opportunities. Any issues - they can pivot - have the cash to enlist specialist ... as they've done so far. Stock will eventually make it' ...more  
Comment by baggerx99 on Nov 21, 2022 8:08pm
Lots of brain power working all aspects of piecing together a winning novel safe effective drug.Have the IP longevity extended to optimize reward for a partnering deal. Drug formulated for acute pain indication and broadening the application, and suited for a more timely deveopment path. Many years of learning to make it right. IMHO, I truly believe they have it this time, keen opinion to say this ...more  
Comment by MrMugsy on Nov 22, 2022 10:08am
Two definite angles at play here (IMO): 1.  reduce the risk with OTENA and bring as much on the acute/chronic side to market over time.           - this will add to our desirability in partnering deals for OTENA           - strike early with a less important geography (e.g. Japan)           - better financial deal if ...more  
Comment by guilelesscat on Nov 22, 2022 12:31pm
And assuming good P2-Bunionectomy results, the SP will jump up to at least $3. otherwise. The stock will crater, and we'll be sitting at below 20 cents.  Place your bets.
Comment by guilelesscat on Nov 22, 2022 2:30pm
For me, I'm all in at 150k shares. Dan either going bring me to an early retirement or grave. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities